We can state that this study contributes to a better comprehension of the involvement of adenosine signaling pathway in lung disease, and in particular, the role of A3AR agonists in an animal model of lung fibrosis; we can hypothesize that MRS5980 or other A3AR selective agonists could represent a potential therapeutic strategy for the treatment of patients with chronic lung inflammation and fibrosis development, even if several aspects require further investigation. This evidence concerns the gene ADORA3 and lung disorder.